Chongqing Yuanlun Biotechnology

Chongqing Yuanlun Biotechnology is a Chinese biopharmaceutical company focused on the development of next-generation allogeneic cell therapies for the treatment of cancer. The company specializes in the engineering of Natural Killer (NK) cells to enhance their anti-tumor activity and persistence within the immunosuppressive tumor microenvironment. Their primary research efforts are directed toward developing "off-the-shelf" cell products that target various solid tumors, including liver and colorectal cancers. By leveraging advanced cell expansion and modification technologies, Yuanlun Biotechnology aims to provide more accessible and effective immunotherapy options for patients with refractory malignancies.